Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Diamond BioFund Inc., established in 2013, is a Taipei-based venture capital firm recognized as the first publicly listed evergreen venture capital firm dedicated to biotech investments in Taiwan. The firm operates under the ticker 6901 on the Taiwan Stock Exchange and was founded with backing from prominent financial institutions including Fubon Financial Holding, Taishin Financial Holding, and Ruentex Group. Diamond BioFund focuses on biotechnology and medical investments, aiming to drive innovation in drug research and development, medical equipment, and agricultural biotech.
As of 2023, Diamond BioFund has approximately NT$8-10 billion in assets under management (AUM), equivalent to roughly US$250-313 million. The firm continues to invest in early-stage biotech startups while also targeting capital for mergers and acquisitions and the development of mid-to-late-stage biotech products. Its mission includes facilitating the entry of Taiwan's biotech innovations into global markets, particularly the United States and European Union.
Diamond BioFund specializes in early-stage biotech startups and mid-to-late-stage biotech products. The firm invests across various stages, including pre-seed, seed, Series A, Series B, Series C, Series D, and growth equity. Its investment strategy emphasizes sectors such as biotechnology, healthcare, medical devices, and digital health. The firm seeks to support the development of innovative medical solutions and facilitate the entry of Taiwan's biotech innovations into global markets.
Diamond BioFund's thesis revolves around leveraging evergreen capital and a specialized life-sciences team to back globally competitive biotech companies. The firm particularly focuses on new drug development, high-end medical equipment, and agricultural biotechnology. It aims to enhance the commercialization potential of its investments by providing global market entry support and risk management across the biotech value chain.
Diamond BioFund has a diverse portfolio that includes several notable companies:
These investments reflect Diamond BioFund's commitment to supporting groundbreaking advancements in the biotech sector.
William Lu / Ching-Ming Lu (Chairman) — William Lu, also known as Ching-Ming Lu, is the chairman of Diamond BioFund. He has been instrumental in discussing the firm's evergreen fund strategy and its focus on global biotech market opportunities.
You-Mei Wu (President / Executive) — You-Mei Wu serves as the CEO and president of Diamond BioFund. She is also recognized as a spokesperson and associate vice president, overseeing compliance and strategic initiatives.
Shu-Ling Cheng (General Manager / Executive) — Shu-Ling Cheng is identified as a senior personnel member at Diamond BioFund, contributing to the firm's operational strategies.
Yen Cheng Huang (Vice President) — Yen Cheng Huang holds the position of vice president, playing a key role in the firm's investment decisions and strategic direction.
Li-Lun Wang (Financial Officer) — Li-Lun Wang serves as the financial officer, responsible for managing the firm's financial operations and reporting.
In 2023, Diamond BioFund made headlines as the first publicly listed evergreen biotech venture capital firm on the Taiwan Stock Exchange. This milestone reflects the firm's commitment to supporting biotech innovation in Taiwan and beyond.
In 2024, Diamond BioFund was featured in Healthcare+ B2B for its fundraising updates, highlighting its ongoing efforts to attract capital for biotech investments. Additionally, GBI Monthly reported on the firm's strategic initiatives in August 2025, showcasing its active role in the biotech investment landscape.
As of January 2026, EMIS noted Diamond BioFund's continued focus on enhancing its portfolio through strategic investments and partnerships within the biotech sector.
What stages does Diamond BioFund invest in?
Diamond BioFund invests in various stages, including pre-seed, seed, Series A, Series B, Series C, Series D, and growth equity.
What sectors does Diamond BioFund focus on?
The firm focuses on biotechnology, healthcare, medical devices, and digital health sectors.
How can I pitch my startup to Diamond BioFund?
Specific details regarding the pitch process are not disclosed. However, it is advisable to prepare a comprehensive pitch deck highlighting your startup's scientific depth, clinical potential, and commercialization pathway.
What is the geographic focus of Diamond BioFund?
Diamond BioFund has a global investment strategy, with a particular emphasis on facilitating the entry of Taiwan's biotech innovations into the US and EU markets.
What value does Diamond BioFund add to its portfolio companies?
The firm provides access to a specialized team with expertise in clinical development, capital markets, and M&A pathways, enhancing the commercialization potential of its investments.
What are the check sizes for investments?
Specific check sizes are not disclosed, but the firm targets early-stage and mid-to-late-stage biotech products.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.